BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)
July 14, 2023 05:53 PM EDTUpdated July 17, 06:12 AM
R&D

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Kyle LaHucik

Senior Reporter

Drew Armstrong

Executive Editor

Bridge­Bio said it would share da­ta on a crit­i­cal Phase III tri­al on Mon­day morn­ing, in what’s ex­pect­ed to be a make-or-break mo­ment for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times